Table 2.
[11C]Raclopride BPND for Striatal Subregions in Placebo and Alcohol Conditions and Percent Change in BPND (ΔBPND) for FHP, FHN, and AUD Groups
| ROI | FHP (n = 16) | FHN (n = 32) | AUD (n = 15) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BPND Placebo | BPND Alcohol | ΔBPND (%) | pa | BPND Placebo | BPND Alcohol | ΔBPND (%) | pa | BPND Placebo | BPND Alcohol | ΔBPND (%) | pa | |
| VST | 2.30 ± 0.25 | 2.13 ± 0.24 | −7.2 ± 6 | <.01 | 2.43 ± 0.28 | 2.25 ± 0.26 | −6.5 ± 8 | <.01 | 2.37 ± 0.27 | 2.23 ± 0.21 | −5.6 ± 6 | <.01 |
| PreDCA | 2.44 ± 0.23 | 2.33 ± 0.26 | −4.7 ± 7 | .01 | 2.77 ± 0.37 | 2.62 ± 0.36 | −3.7 ± 8 | <.01 | 2.76 ± 0.30 | 2.62 ± 0.20 | −4.6 ± 7 | .02 |
| PreDPU | 3.00 ± 0.31 | 2.88 ± 0.34 | −4.0 ± 7 | .02 | 3.30 ± 0.37 | 3.14 ± 0.35 | −3.5 ± 7 | <.01 | 3.27 ± 0.27 | 3.16 ± 0.21 | −3.2 ± 6 | >.05 |
| PostCA | 1.84 ± 0.40 | 1.78 ± 0.36 | −2.4 ± 10 | >.05 | 1.89 ± 0.34 | 1.78 ± 0.31 | −4.1 ± 14 | .03 | 1.92 ± 0.29 | 1.75 ± 0.28 | −5.0 ± 8b | .04 |
| PostPU | 3.21 ± 0.33 | 3.10 ± 0.27 | −3.0 ± 7 | >.05 | 3.34 ± 0.32 | 3.21 ± 0.33 | −3.0 ± 6 | .01 | 3.33 ± 0.42 | 3.24 ± 0.30 | −2.1 ± 8 | >.05 |
Values represent mean ± SD.
AUD, alcohol use disorder; BPND, binding potential; FHN, family history–negative; FHP, family history–positive; PostCA, postcommissural caudate; PostPU, postcommissural putamen; PreDCA, precommissural dorsal caudate; PreDPU, precommissural dorsal putamen; ROI, region of interest; VST, ventral striatum.
a
Paired t test; note that p < .001 for each striatal subregion when all subjects’ data are pooled across groups.
b
After removal of one outlier in the AUD group with PostCA ΔBPND more than 3 SDs above the mean.